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Background/aim: Smokeless tobacco has been associated with oral cavity cancer for several decades. The incidence of oral cavity cancer
is higher in some parts of the world especially South and South-East Asia including Pakistan. The aim of current study was to evaluate
the risk of oral cavity cancer among smokeless tobacco users in our country.
Materials and methods: A case-control study was conducted between November 2016 and September 2017. Patients diagnosed with
oral cavity cancer receiving treatment were included as cases and the attendants of various cancer patients visiting the hospital during
the study period were included in the study as controls. Odds ratios (OR) and 95% confidence intervals (CI) were calculated and all
reported P-values were considered significant at < 0.05.
Results: The crude OR for the “ever smokeless tobacco users” among cases and controls came out to be 4.98 (95%CI; 2.76–9.01). The
OR for snuff users among cases and controls was 4.82 (95%CI; 2.37–9.80) and that for betel leaf users was 4.42 (95%CI; 1.66–11.91) after
adjusting for smoking and age.
Conclusion: Our study provided strong evidence for snuff and betel leaf to be independent risk factors for oral cavity cancer.
Key words: Smokeless tobacco, risk, snuff, oral cavity

1. Introduction
International Agency for Research on Cancer (IARC)
in 2006 declared that smokeless tobacco (SLT) is
carcinogenic in human beings, causing cancer of the oral
cavity and pancreas. Wide variability amongst geographic
regions in the type and extent of disease caused by the use
of smokeless tobacco was observed by IARC and disease
dissimilarities were attributed to the large differences in
the concentrations of carcinogens in the tobacco used in
different regions [1–5].
Smokeless tobacco has capricious modes of
consumption from chewable tobacco not mixed with
any other ingredient to a mixture of tobacco with other
ingredients such as betel leaf (locally called “paan”), snuff
(locally called “naswar”), supari, chalia, and Mishri [6]. It
contains a number of carcinogens including non-volatile
alkaloid-derived tobacco-specific N-nitrosamine and
N-nitrosamino acids. In addition, some other carcinogens
such as volatile aldehydes, and some poly-nuclear agents
have also been identified in SLT [7].
The most prevalent form of the oral cavity cancer in
South and South East Asia is squamous cell carcinoma

(approximately 90%) because of cultural use of betelleaf and different forms of smokeless tobacco while the
other forms are adenocarcinoma of the salivary glands,
malignant melanoma, and adenoid cystic carcinoma.
Pakistan is one of the countries where the use of SLT
is a culturally acceptable habit. Oral cavity cancer has
become the most common cancer among men and
the second most common cancer among both sexes in
Pakistan [8]. An estimated 6000 Pakistanis lose their lives
because of oral cavity cancer every year [9]. Studies from
Karachi demonstrate that snuff is a major contributor in
the aetiology of oral cavity cancer in Pakistan [8].
We conducted a hospital based case-control study
with the aim to further evaluate the risk of oral cavity
cancer by the use of various smokeless tobacco products.
Rationale of the study was that there has been no casecontrol study done in the past in our region to show
direct association of smokeless tobacco use and risk of
oral cavity cancer. Moreover, most common smokeless
tobacco consumed in our region is snuff in contrast to
the other regions where betel leaf, supari, and chalia are
more common.
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2. Materials and methods
A case-control study was conducted at INMOL Hospital,
Lahore between November 2016 and September 2017.
Patients diagnosed with oral cavity cancer receiving
treatment at INMOL Hospital were included in the study
as cases and the attendants of various cancer patients
visiting the hospital during the study period were selected
as controls. A case was defined as a person aged 19 years
and above with laboratory confirmed primary diagnosis of
oral cavity cancer. All cases that were histopathologically
diagnosed as oral cavity cancer on or after January 1, 2016
and visited the hospital during the study period were
included. Cases diagnosed before the beginning of 2016,
metastatic lesions in the oral cavity from other sites and
tumours of major salivary glands were excluded from our
study. People with history of diseases or conditions which
could have causal association with oral cavity cancer were
also excluded to limit confounding factors. This included
alcohol consumption, uncontrolled diabetes, poor fitting
dentures, and Lichen Planus. To ensure relative ethnic and
socioeconomic similarity with cases, a control was defined
as a person aged 19 years and above not having oral cavity
cancer, who visited INMOL as an attendant of a case
selected for our study. Ethical approval of the study was
obtained from Institutional Review Board and informed
verbal consent was taken from the participants.
2.1. Data collection
Sample size consisted of 90 cases and 120 controls. The
cases and controls were personally interviewed using a
structured questionnaire. The questionnaire included
questions regarding demographic information such as
age, gender, literacy level, province, and subsite of tumour.
The second part of the questionnaire aimed at questions
on the use of smokeless tobacco, which comprised
questions on type, frequency, and duration of the habits.
“Ever smokeless tobacco users” were defined as those who
had used smokeless tobacco at least 20 times in their life.
Age was categorized into 15-year bands from 19–60 years
and participants above 60 years of age were categorized
separately.
2.2. Statistical methods
Frequencies with percentages were used for categorical
variables. Chi square test was used for calculating P-values
in categorical variables. All reported P-values were
calculated with significance considered at P < 0.05. Crude
(unadjusted) Odds ratios (OR) with 95% confidence
interval (95%CI) were calculated and then adjusted for
potential confounders, i.e. age, gender, and smoking
using multinomial logistic regression analysis. Never SLT
users, male gender, age of >50 years, and never smokers
served as reference category in logistic regression analysis.
Statistical analysis was performed using SPSS version
20.0 (IBM Corp., Armonk, NY, USA). Tumour sites were
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categorized according to the International Classification
of Diseases, Tenth Revision (ICD-10). The staging system
used for oral cavity cancer was TNM classification system
2010, 7th edition, maintained by The American Joint
Committee on Cancer (AJCC) and the International
Union for Cancer Control (UICC).
3. Results
3.1. Sample characteristics
Mean age of the controls was 52.04 years (Range: 22–69, ±
SD 11.17) and for cases it was 57.38 years (Range: 40–70,
± SD 6.88).Majority of study participants were in the age
group between 46–65 years (Table 1). Cases and controls
were age matched (P = 0.090), (Table 1). Of the 90 cases,
62.2% were males and 37.8% were females (P < 0.001)
as shown in Table 1. Male to female ratio was 1.65:1. Of
the 120 controls, the males and females were 88.3% and
11.7%, respectively (P <0.001). In our control group male
to female ratio was 7.5:1. The major participants in cases
and controls were from the provinces of Punjab and KPK
(e.g., among cases 46.2% and 40.0%, respectively). Also,
there were 6.7% of cases from Gilgit Baltistan and Azad
Kashmir. No geographical differences occurred between
cases and controls (P = 0.625).The large proportion of
participants was illiterate both in cases and controls (62.2%
vs. 56.7%). 17.8% of cases had completed primary level of
education and 4.4% had completed graduation (so the
questionnaire used during data collection was designed in
their local languages as lack of understanding of English or
Urdu among participants, especially among KPK females,
was common).Smoking status was similar in both cases
and controls (0.134). Use of SLT products was significantly
high in cases as compared to controls (P <0.001). Out of 90
cases, 58 (64.4%) had the habit of SLT use while out of 120
controls, 32 (26.7%) had this habit (Table 1).
3.1.1. Tumour subtypes and staging
Oral tongue carcinoma and alveolar ridge (upper or
lower) carcinoma were detected in 24.4% of cases followed
by buccal mucosa cancer in 20.0% of cases. Rest of the
subsites included floor of mouth in 8.9% of cases and lips
in 17.7% of cases. Only 4.4% of cases were having cancer
of Retro molar trigone and there was no case of hard palate
cancer (Figure 1).
The Tumour size (T) according to AJCC TNM (7th
edition) staging was classified as T4 in 40.0% cases and T3
in 35.5% cases. The nodal involvement (N) was seen in
most cases with 42.2% having N1 disease and 31.1% having
N2 disease. It was interesting to see that almost all the cases
were not having distant metastases (Table 2).
3.2. Smokeless tobacco users
In our study, 40.0% of cases consumed snuff compared
to 16.7% of controls; 6.7% of cases used supari/chalia

KHAN et al. / Turk J Med Sci
Table 1. Baseline characteristics of cases and controls.
Age (years)

Cases

Controls

19–30

0

10 (8.3%)

31–45

8 (8.9%)

18 (15%)

46-60

58 (64.4%)

66 (55%)

>60

24 (26.7%)

26 (21.7%)

P-values

0.090

Gender
Male

56 (62.2%)

106 (88.3%)

Female

34 (37.8%)

14 (11.7%)

Federal

6 (6.7%)

14 (11.7%)

Punjab

42 (46.7%)

55 (45.8%)

KPK

36 (40%)

42 (35%)

Baluchistan

0

0

GilgitBaltistan/Azad Kashmir

6 (6.7%)

9 (7.5%)

Sindh

0

0

<0.001

Province

0.625

Literacy
Primary

16 (17.8%)

30 (25.0%)

Middle

0

10 (8.3%)

High / Intermediate

14 (15.5%)

12 (10.0%)

Graduate

4 (4.4%)

0

Illiterate

56 (62.2%)

68 (56.7%)

Ever smokers

18 (20%)

16 (13%)

0.134

SLT users

58(64.4%)

32(26.7%)

<0.001

0.003

Smoking status:

compared to 3.3% of controls;1 7.7% of cases consumed
betel leaf compared to 6.7% of controls (Figure2).
3.3. OR calculation
The OR was calculated for the ever smokeless tobacco
(SLT) users among cases and controls; it came out to
be 4.98 (95%CI; 2.76–9.01) with p-value of <0.0001 as
shown in Table 3. After adjusting for age and smoking the
adjusted OR came out to be 4.71 (95%CI; 2.53–8.74) which
was again highly significant (P < 0.001). After adjusting for
gender, females had highly significant (P < 0.001) manyfold increased risk of oral cavity cancer as compared to
men in our study participants and the OR value increased
up to 28.29 (95%CI; 9.93–80.52), (Table 3).
The adjusted OR of snuff users was the highest being
4.82 (95%CI; 2.37–9.80) with P-value of <0.001 when
adjusted for age and smoking. For supari/chalia users, the
OR was 4.67 (95%CI; 1.14–19.12) with P-value of 0.032.
For betel leaf users, the OR was 4.42 (95%CI; 1.66–11.91)
with P-value of 0.003 as shown in Table 3.

Subjects with snuff and betel leaf use were significantly
associated with oral cavity risk after adjustment with age,
gender, and smoking (Table 3).
3.4. Tumour characteristics among snuff users
The most common subsites of oral cavity cancer found in
these participants were alveolar ridge (50%) and buccal
mucosa (28%). The T3 size (39%) and N2 (42%) node stage
of the tumour was found to be more prevalent among snuff
users and the patients were found in maximum numbers
with Stage III disease (47%).
3.4.1. Snuff use and its duration
Snuff users were divided into 3 groups based on their
duration of snuff use, i.e. less than 10 years, 10–20 years
and more than 20 years. These groups were then compared
separately with never users of any smokeless tobacco
products. The OR was found to be higher than 1 in all
groups with the highest being in those with more than 20
years history of snuff use (OR = 4.52 and P-value < 0.001),
(Table 3). Daily and weekly users were more prone to oral
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Hard palate, 0

Table 2. Frequency distribution of cases by their TNM stage.

Retromolar
trigone, 4

Floor of mouth,
8

Lips, 16

Oral tongue, 22

Alveolar ridges,
22

Buccal
mucosa, 18

Figure 1. Frequency Distribution of cases by their tumour
subsites.

Tumour Size (T)

No. of Cases

T1

10 (11.1%)

T2

22 (24.4%)

T3

32 (35.5%)

T4

36 (40.0%)

Node status (N)
N0

10 (11.1%)

N1

38 (42.2%)

N2

28 (31.1%)

N3

14 (15.5%)

Distant mets (M)
M0

90 (100%)

M1

0

Grade
G I (well-differentiated)

10 (11.1%)

cavity cancer while infrequent users had no significant
association with oral cavity cancer (P = 0.261) despite an
OR of 2.20 (Table 3).
Frequency and duration of smokeless tobacco use
among cases and controls are expressed in Figure 3 while
frequency and duration of SLT use were prevalent among
cases as compared to the control subjects (Figure 3).

G II (moderately differentiated)

22 (24.4%)

G III (poorly differentiated)

30 (33.3%)

G IV (undifferentiated)

12 (13.3%)

Missing data

16 (17.8%)

4. Discussion
The use of SLT is common among different South Asian
countries like Pakistan and India. Commonly available
smokeless tobacco products in Pakistan include snuff
and betel leaf while less commonly available ones include
gutka, supari/chalia, and some chewing tobacco.
Present study was intended as a pilot project to evaluate
the risk of oral cavity cancer in Pakistani population
using smokeless tobacco products. We have observed a
positive association between use of smokeless tobacco
and oral cavity cancer among participants. OR for the ever
smokeless tobacco users was calculated. The participants
who consumed smokeless tobacco were approximately
5 times (OR = 4.98) more likely to get oral cavity cancer
compared to never smokeless tobacco users. This value
was statistically significant with P-value of 0.0001. Such
a marked and statistically significant increase in OR
warrants the need for a future study with a much larger
sample size to ensure adequate study power.
Our findings are consistent with studies conducted
in other countries of the region reporting the oral cavity
cancer specific relative risk ranging from 1.2–12.9 with the
use of SLT. The pooled OR for chewing tobacco and risk of
oral cancer has been calculated as 4.7(3.1–7.1) in a recent
meta-analysis comparing the studies in South Asia [9–11].
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Anatomic stage
Stage I

0

Stage II

12 (13.3%)

Stage III

38 (42.2%)

Stage IV

40 (44.4%)

However, some differences associated with risk estimates
were observed in the populations predominantly using
Gutka and Betel-quid or snuff as a medium. The enormity
of risk for oral cancer is linked with the use of snuff in
comparison with other SLT products. The estimated OR
for snuff users vs. never users rises up to 23.7(6.9–81.0)
[10].
Studies from Europe and North America have reported
the relative risk of 1.8 (1.1-2.9) for developing oral cancer
by using SLT products [12]. Regional disparity among
studies for relative risk of developing oral cancer may
reflect the variance of SLT products used in different
regions. Snuff contributes to about 40% of oral cancers
in the study region. The participants of our study who
consumed supari/chalia were having adjusted for age and
smoking, OR of 4.67 (statistically significant with P-value
of 0.032). For betel users, the OR showed 4.4 times (OR
= 4.42) more likelihood of getting oral cavity cancer in
comparison to nonusers. The participants who were snuff
users had 4.82 times greater likelihood of developing
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Cases

73.3%

Controls

40%

33.3%
16.7%

0

6.7%

0

Gutka

17.7%
6.7%

3.3%

Supari/chalia Snuff ( Naswar) Paan/Betel leaf

0

0

Others

Nothing

Figure 2. Smokeless tobacco users among cases and controls.
Table 3. Association of oral cavity cancer with smokeless tobacco (SLT) use in study subjects.
Variables

Cases
Controls
Unadjusted OR 95% CI
(n = 90) (n = 120)

Adjusted ORa

95% CIa

Adjusted ORb 95% CIb

SLT users

58

32

4.98

2.76–9.01

4.71

2.53–8.74

28.29

Never user

32

88

1.00 (referent)

-

1.00 (referent) -

1.00 (referent)

Snuff

36

20

4.95

2.51–9.77

4.82

32.65

Betel leaf

16

8

5.50

2.15–14.08 4.42

1.66–11.91 23.18

6.23–86.2

Supari/chalia

6

4

4.12

1.09–15.57 4.67

1.14–19.12 21.09

3.59–123.6

Never users

32

88

1.00 (referent)

-

1.00 (referent) -

<10 years

10

5

3.70

1.20–11.4

5.45

1.59–18.71 21.44

4.89–94.01

10–20 years

4

6

1.23

0.33–4.56

1.73

0.43–6.99

5.81

1.23–27.45

>20 years

22

9

4.52

1.95–10.52 3.25

1.37–7.71

6.45

2.50–16.65

Never users

54

100

1.00 (referent)

-

Daily

5.22

2.66–10.27 5.22

2.56–10.65 34.5

11.2–106.1

Frequently in a week

6.60

2.16–20.2

6.80

2.09–22.1

45.8

9.74–216.1

Weekly

5.50

0.961–31.5 4.82

0.76–30.4

32.4

3.64–287.8

Frequently in a month

2.20

0.56–8.71

1.43

0.35–5.83

5.48

0.97–31.03

No

1.00 (referent)

-

1.00 (referent) -

9.93–80.52

Type of SLT used:
2.37–9.80

10.6–100.4

1.00 (referent) -

Duration of snuff use:

1.00 (referent) -

1.00 (referent) -

Frequency of snuff use:

1.00 (referent) -

a: OR adjusted for age (<50 and >50 years) and smoking (never vs. ever smokers).
b: OR adjusted for age (<50 and >50 years), gender, and smoking (never vs. ever smokers).

oral cavity cancer as compared to nonusers (P < 0.001),
(Table 4). Use of SLT products in females increases the
likelihood of oral cavity cancer up to 28.29 times (9.93–
80.52), Table 3. This may be due to a reduced basal risk
of oral malignancy among Pakistani women due to lower
prevalence of alcohol consumption and smoking among
them, 2 other major risk factors for developing oral cancer.
It is also in line with South Asian studies where OR among
women ranged between 6.5–45.8 in women in contrast to

men having values between 1.5–10.9 [10]. Keeping in view
the many fold increase in risk of oral cavity cancer among
women, we have adjusted ORs with age and smoking
separately and age, gender, and smoking in the last column
of Table 3 to outweigh the effect of gender in the cancer
risk (Table 3). Duration and frequency of snuff use also
had impact on OR of oral cavity cancer risk which is also
in concordance with other South Asian studies [10].
Our study showed that the most common risk factor
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64.4
Cases

42.2%

Controls

26.7
18.3%

17.8

13.3%
3.3% 4.4% 1.7% 4.4 3.3

Daily

Frequently in
a week

Weekly

Frequently in
a month

6.7

0 0
Monthly

< 10 years

11.7

10-20 years

26.7%

20
8.3
>20 years

Ovarall

Figure 3. Frequency and duration of smokeless tobacco use among cases and controls
expressed in percentages.

for oral cavity cancer was snuff and common sub-site in
cases that consumed snuff was buccal mucosa and alveolar
ridge (upper/lower). The literature issued by IARC on
smokeless tobacco use showed that maximum number of
cases were reported of buccal mucosa cancer in snuff users
as these regions of oral cavity come in direct contact of
the snuff [5]. Also a meta-analysis published on smokeless
tobacco use among head and neck cancer cases showed
that snuff use was more frequently associated with buccal
mucosa cancer [7].
Similar to the other case-control studies, one of the
main limitations of the study was recall-bias and selectionbias to some extent. To minimize recall-bias, the cases
diagnosed on and after January 1, 2016 were selected.
The proportion of females in the control group was less.
The probable reason could be lack of privacy in a hospital
setting. Another limitation is that the subjects were derived
from a hospital and therefore, may not approximate the
relative risk for the general population. Furthermore,
large studies are needed which should examine smokeless
tobacco use separately from joint smoking and smokeless
tobacco use to predict its association with oral cavity
cancer among both types of users.
In spite of the limitations, our study came out with
the conclusion that the use of smokeless tobacco results
in exposure to potent carcinogens. Our studies showed a
positive association between ever use of smokeless tobacco
and risk of oral cavity cancer. Snuff was consumed by
maximum participants in our study. It showed association

with increase in duration of snuff use as more than 20 yearusers have more likelihood of getting oral cavity cancer
than never users of snuff. Also, the use of betel showed
positive association with oral cavity cancer risk.
In conclusion, our study showed a statistically
significant positive association between use of smokeless
tobacco and risk of oral cancer in patients presenting to
our Institute from the north and centre of Pakistan, even
more so in women. Literature review shows that this is
in line with similar studies carried out in the region and
other parts of the world. A higher powered study with
sampling from other parts of the country could help in
better understanding of disease epidemiology as well as
has a greater impact on public awareness.
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